Meet our Partners and Collaborators
At InMed Pharmaceuticals, we’ve teamed up with vendors and collaborators who are world leaders in their respective fields and bring specific skill sets to our programs. This sharing of knowledge and capabilities supports our R & D efforts while helping to advance our cannabinoid manufacturing and therapeutic programs.
If you are interested in collaborating with InMed Pharmaceuticals or would like to learn more, contact us.
EyeCRO
The licensing agreement with EyeCRO grants InMed an exclusive, worldwide license to develop and commercialize prospective therapeutic cannabinoid formulations utilizing the MiDROPS® delivery technology.
For more information, read the full press release here.
About EyeCRO
EyeCRO is an ophthalmic contract research organization that helps companies advance development of vision-saving therapeutics. The Company offers a number of preclinical models as well as formulation services using the innovative and patented MiDROPS® platform. For more information, visit www.EyeCRO.com.
Almac Group
Announced in May 2020, InMed and Almac are engaged in developing a streamlined cannabinoid manufacturing process, specifically optimizing the upstream cannabinoid assembly processes as well as downstream purification, to achieve cost-efficient, GMP-grade active pharmaceutical ingredients for prescription-based medications.
For more information, read full press release here.
About Almac Group
The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialization, API manufacture, analytical services, formulation development, clinical trial supply, Interactive Response Technology through to commercial-scale manufacture. Almac is an international, privately-owned organization which has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia. For more information please visit www.almacgroup.com.
National Research Council of Canada (NRC) Industrial Research Assistance Program (IRAP)
InMed Pharmaceuticals receives funding through National Research Council of Canada’s (NRC) Industrial Research Assistance Program (IRAP) to support our technology development.
About the National Research Council of Canada (NRC)
The National Research Council of Canada (NRC) is Canada’s largest federal research and development organization.
The NRC partners with Canadian industry to take research impacts from the lab to the marketplace, where people can experience the benefits. This market-driven focus delivers innovation faster, enhances people’s lives and addresses some of the world’s most pressing problems. We are responsive, creative and uniquely placed to partner with Canadian industry, to invest in strategic R&D programming that will address critical issues for our future. https://nrc.canada.ca/
The University of British Columbia – Dr. Ujendra Kumar of the faculty of Pharmaceuticals Sciences
The collaboration, entitled “Pharmacological characterization of phytocannabinoids and the endocannabinoid system” will investigate the potential therapeutic effects of selected rare cannabinoid analogs in neurodegenerative diseases.
Dr. Ujendra Kumar of the faculty of Pharmaceuticals Sciences at UBC has been awarded an Alliance grant from NSERC, with InMed as the named industry partner. The funding will support the research and development studies of InMed’s cannabinoid pharmaceutical candidates for neurodegenerative diseases.
Read about the study in this press release.
About the University of British Columbia
The University of British Columbia (UBC) is a global centre for teaching, learning and research, consistently ranked among the top 20 public universities in the world and recently recognized as North America’s most international university. https://www.ubc.ca/
The University of British Columbia – Dr. Vikramaditya Yadav
The collaboration, entitled ‘Microbial metabolic engineering for cannabinoid biosynthesis’, targets development of a microbial-based cannabinoid expression system for the manufacture of individual cannabinoid drugs for treating diseases with high unmet medical need.
For more information, watch this video as UBC’s Dr. Yadav Talks about How Biosynthesis May Efficiently Produce Cannabinoids.
About the University of British Columbia
The University of British Columbia (UBC) is a global centre for teaching, learning and research, consistently ranked among the top 20 public universities in the world and recently recognized as North America’s most international university. https://www.ubc.ca/
BayMedica Inc. (subsidiary of InMed)
Our relationship with BayMedica started as a research collaboration whereby BayMedica was assessing the potential of one or more of InMed’s high-efficiency enzyme gene sequences in BayMedica’s systems for the production of the cannabinoids in BayMedica’s catalogue.
During our research collaboration, it was quickly evident how well our teams worked together and that there was synergy in our manufacturing technologies. On October 13th, InMed completed its acquisition of BayMedica.
We are excited to join forces with the talented team at BayMedica and work together to make rare cannabinoids more accessible through our combined cannabinoid manufacturing technologies.
For more information, read the full press release here.
